These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

474 related items for PubMed ID: 15070658

  • 1. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.
    Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Giles F, Rios MB, Shan J, Letvak L, Thomas D, Faderl S, Ferrajoli A, Cortes J.
    Blood; 2004 Apr 15; 103(8):2873-8. PubMed ID: 15070658
    [Abstract] [Full Text] [Related]

  • 2. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
    Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, Goh YT, Rosti G, Nakamae H, Gallagher NJ, Hoenekopp A, Blakesley RE, Larson RA, Hughes TP.
    Lancet Oncol; 2011 Sep 15; 12(9):841-51. PubMed ID: 21856226
    [Abstract] [Full Text] [Related]

  • 3. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.
    Kantarjian HM, Cortes J, O'Brien S, Giles FJ, Albitar M, Rios MB, Shan J, Faderl S, Garcia-Manero G, Thomas DA, Resta D, Talpaz M.
    Blood; 2002 May 15; 99(10):3547-53. PubMed ID: 11986206
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Spotlight on imatinib mesylate in chronic myeloid leukemia.
    Curran MP, Croom KF, Goa KL.
    BioDrugs; 2004 May 15; 18(3):207-10. PubMed ID: 15161340
    [Abstract] [Full Text] [Related]

  • 7. Targeted chronic myeloid leukemia therapy: seeking a cure.
    Fausel C.
    J Manag Care Pharm; 2007 Oct 15; 13(8 Suppl A):8-12. PubMed ID: 17970609
    [Abstract] [Full Text] [Related]

  • 8. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
    Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, Ossenkoppele GJ, Nicolini FE, O'Brien SG, Litzow M, Bhatia R, Cervantes F, Haque A, Shou Y, Resta DJ, Weitzman A, Hochhaus A, le Coutre P.
    Blood; 2007 Nov 15; 110(10):3540-6. PubMed ID: 17715389
    [Abstract] [Full Text] [Related]

  • 9. Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia.
    Wang L, Pearson K, Pillitteri L, Ferguson JE, Clark RE.
    Br J Haematol; 2002 Sep 15; 118(3):771-7. PubMed ID: 12181044
    [Abstract] [Full Text] [Related]

  • 10. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
    Kantarjian HM, O'Brien S, Cortes J, Giles FJ, Rios MB, Shan J, Faderl S, Garcia-Manero G, Ferrajoli A, Verstovsek S, Wierda W, Keating M, Talpaz M.
    Cancer; 2003 Dec 15; 98(12):2636-42. PubMed ID: 14669283
    [Abstract] [Full Text] [Related]

  • 11. High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study.
    Petzer AL, Wolf D, Fong D, Lion T, Dyagil I, Masliak Z, Bogdanovic A, Griskevicius L, Lejniece S, Goranov S, Gercheva L, Stojanovic A, Peytchev D, Tzvetkov N, Griniute R, Oucheva R, Ulmer H, Kwakkelstein M, Rancati F, Gastl G.
    Haematologica; 2010 Jun 15; 95(6):908-13. PubMed ID: 20145273
    [Abstract] [Full Text] [Related]

  • 12. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia.
    Kantarjian HM, Talpaz M, O'Brien S, Jones D, Giles F, Garcia-Manero G, Faderl S, Ravandi F, Rios MB, Shan J, Cortes J.
    Blood; 2006 Sep 15; 108(6):1835-40. PubMed ID: 16709931
    [Abstract] [Full Text] [Related]

  • 13. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
    Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM, ENESTnd Investigators.
    N Engl J Med; 2010 Jun 17; 362(24):2251-9. PubMed ID: 20525993
    [Abstract] [Full Text] [Related]

  • 14. The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML.
    O'Dwyer ME, Mauro MJ, Kurilik G, Mori M, Balleisen S, Olson S, Magenis E, Capdeville R, Druker BJ.
    Blood; 2002 Sep 01; 100(5):1628-33. PubMed ID: 12176881
    [Abstract] [Full Text] [Related]

  • 15. Hematopathologic and cytogenetic findings in imatinib mesylate treated chronic myelogenous leukemia patients: 2.5 years' experience.
    Cojbasić I, Macukanović-Golubović L.
    Vojnosanit Pregl; 2010 Oct 01; 67(10):802-6. PubMed ID: 21061842
    [Abstract] [Full Text] [Related]

  • 16. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha.
    Cortes J, Giles F, O'Brien S, Thomas D, Garcia-Manero G, Rios MB, Faderl S, Verstovsek S, Ferrajoli A, Freireich EJ, Talpaz M, Kantarjian H.
    Blood; 2003 Jul 01; 102(1):83-6. PubMed ID: 12637317
    [Abstract] [Full Text] [Related]

  • 17. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
    Cohen MH, Johnson JR, Pazdur R.
    Clin Cancer Res; 2005 Jan 01; 11(1):12-9. PubMed ID: 15671523
    [Abstract] [Full Text] [Related]

  • 18. The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment.
    Zonder JA, Pemberton P, Brandt H, Mohamed AN, Schiffer CA.
    Clin Cancer Res; 2003 Jun 01; 9(6):2092-7. PubMed ID: 12796373
    [Abstract] [Full Text] [Related]

  • 19. Epigenetic therapy with hydralazine and magnesium valproate reverses imatinib resistance in patients with chronic myeloid leukemia.
    Cervera E, Candelaria M, López-Navarro O, Labardini J, Gonzalez-Fierro A, Taja-Chayeb L, Cortes J, Gordillo-Bastidas D, Dueñas-González A.
    Clin Lymphoma Myeloma Leuk; 2012 Jun 01; 12(3):207-12. PubMed ID: 22420986
    [Abstract] [Full Text] [Related]

  • 20. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy.
    Cortes JE, Talpaz M, Giles F, O'Brien S, Rios MB, Shan J, Garcia-Manero G, Faderl S, Thomas DA, Wierda W, Ferrajoli A, Jeha S, Kantarjian HM.
    Blood; 2003 May 15; 101(10):3794-800. PubMed ID: 12560227
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.